Assertio Therapeutics, Inc.(ASRT)

Description: Assertio Therapeutics, Inc. is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), Cambia (diclofenac potassium for oral solution), Xartemis XR and Zipsor (diclofenac potassium). Its NUCYNTA ER (tapentadol extended release tablets) is a product for the management of pain severe enough to require daily long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults, and its NUCYNTA (tapentadol) is a product for the management of moderate to severe acute pain in adults. Its Gralise (gabapentin) is a once-daily product for the management of postherpetic neuralgia (PHN). Its Cambia (diclofenac potassium for oral solution) is a product for the acute treatment of migraine attacks.

---

Keywords: Pharmaceutical Pain Organic Compounds Organ Systems Chemical Compounds Potassium Analgesics Opioids Migraine Neuropathic Pain Acute Pain Peripheral Neuropathy Treatment Of Migraine Amino Acids Diclofenac Diabetic Peripheral Neuropathy Calcium Channel Blockers Gabapentin Postherpetic Neuralgia

---

Home Page: www.assertiotx.com

ASRT Technical Analysis

100 South Saunders Road
Lake Forest, IL 60045
United States
Phone: 224 419 7106

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)